22 documents

Read All
18:56 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Biogen reports Phase IIa data for IPF candidate

In its 3Q17 earnings presentation, Biogen Inc. (NASDAQ:BIIB) said BG00011 (STX-100) achieved "proof of biology" in a Phase IIa trial by showing "substantial" downregulation of the transforming growth factor (TGF) beta pathway as measured by...
Read More
07:00 , Oct 13, 2014 |  BioCentury  |  Regulation

The lung haul

Patients at FDA 's recent workshop on idiopathic pulmonary fibrosis said they want treatments that can halt or reverse the progression of fibrosis and - just as importantly - improve quality of life. But they...
Read More
07:00 , Oct 13, 2014 |  BioCentury  |  Regulation

The lung haul

Patients at FDA 's recent workshop on idiopathic pulmonary fibrosis said they want treatments that can halt or reverse the progression of fibrosis and - just as importantly - improve quality of life. But they...
Read More
07:00 , Sep 8, 2014 |  BioCentury  |  Strategy

Parsing Roche's IPF bet

InterMune Inc. 's third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche . The question...
Read More
07:00 , Jul 31, 2014 |  BC Innovations  |  Cover Story

Fresh air for COPD

An undisclosed company has picked up an integrin-targeting antibody from the University of California, San Francisco that could address the underlying pathology in chronic obstructive pulmonary disease by improving airway remodeling via suppressing transforming growth...
Read More
08:00 , Dec 5, 2013 |  BC Innovations  |  Cover Story

Targeting fibrotic integrin

Fibrosis has long been associated with the activation of transforming growth factor-b by integrin, but the mechanism underlying the process in vivo was not known. Now, an international team has shown that the myofibroblast-expressed integrin...
Read More
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

STX-100: Phase IIa started

Biogen Idec disclosed in its 2Q12 earnings that in July it began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate weekly subcutaneous STX-100 for 8 weeks in 32 IPF patients. The trial includes 4...
Read More
07:00 , Mar 15, 2012 |  BC Innovations  |  Targets & Mechanisms

Halofuginone target ID

A U.S. and South Korean research team has identified the molecular target of halofuginone, a small molecule antifibrotic and anti-inflammatory compound. 1 The findings could help guide the design of next-generation halofuginone analogs with improved...
Read More
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Biogen Idec, Stromedix deal

Biogen Idec will acquire Stromedix for $75 million up front, and up to $487.5 million in milestones. Stromedix is developing STX-100 , a humanized mAb against integrin alpha(V)beta(6) , to treat fibrotic disease. The product...
Read More
08:00 , Feb 20, 2012 |  BioCentury  |  Strategy

Biogen buys back in

Biogen Idec Inc. is buying Stromedix Inc. to re-acquire the anti-fibrotic mAb it cast off five years ago. The big biotech thinks the time is ripe because FDA has clarified a regulatory path in idiopathic...
Read More